Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 07 Feb 2022
Analysis of consumer comments into PBAC decision-making (2014–9)
4 February 2022 - Our objective was to analyse and review consumer comments in the PBAC's decision-making process. ...
Posted by Michael Wonder on 07 Feb 2022
Bladder cancer technology: new improved blue light cystoscopy system receives FDA approval for use in non-muscle invasive bladder cancer in the U.S.
7 February 2022 - Photocure announces U.S. FDA approval of a new and improved blue light system to be used with ...
Posted by Michael Wonder on 07 Feb 2022
FDA investigating possible increased risk of death with lymphoma medicine Ukoniq (umbralisib)
3 February 2022 - The U.S. FDA is investigating a possible increased risk of death with the cancer medicine Ukoniq (umbralisib) ...
Posted by Michael Wonder on 07 Feb 2022
DoH publishes revised agenda for next month's PBAC meeting
7 February 2022 - The revised agenda notes three changes. ...
Posted by Michael Wonder on 07 Feb 2022
Medicines Australia calls for new National Medicines Policy to be pushed back until after the federal election
4 February 2022 - Medicines Australia is today calling for the new National Medicines Policy to be pushed back until ...
Posted by Michael Wonder on 06 Feb 2022
Cytokinetics announces FDA acceptance of new drug application for omecamtiv mecarbil for the treatment of heart failure with reduced ejection fraction
4 February 2022 - PDUFA target action date set for 30 November 2022. ...
Posted by Michael Wonder on 06 Feb 2022
Importing oncology trials from China: a bridge over troubled waters?
4 February 2022 - On 10 February 2022, the US FDA's Oncologic Drugs Advisory Committee will convene to discuss ORIENT-11, a ...
Posted by Michael Wonder on 05 Feb 2022
Confirming the next FDA commissioner is a matter of national preparedness
5 February 2022 - The COVD-19 pandemic has shown in bold relief our lack of national preparedness in the realm of ...
Posted by Michael Wonder on 05 Feb 2022
CADTH establishes new post-market drug evaluation program
4 February 2022 - CADTH is pleased to announce it is expanding its expertise in the management of pharmaceuticals in ...
Posted by Michael Wonder on 05 Feb 2022
TGA approves provisional determination for Gilead for COVID-19 treatment, Veklury (remdesivir), for proposed use in children and adults who are at risk of progressing to severe COVID-19
5 February 2022 - The TGA has granted a second provisional determination to Gilead in relation to its COVID-19 treatment, ...
Posted by Michael Wonder on 05 Feb 2022
Price of COVID treatments from Pfizer, Merck, GSK align with patient benefits
3 February 2022 - The prices of drugs used to treat COVID-19 for those at risk of serious illness are ...
Posted by Michael Wonder on 05 Feb 2022
Health Canada authorises Tecentriq (atezolizumab) for Canadians with early non-small cell lung cancer
4 February 2022 - Tecentriq (atezolizumab) is the first and only cancer immunotherapy approved for non-small cell lung cancer in the ...
Posted by Michael Wonder on 04 Feb 2022
To hell and back: devices meant to ease pain are causing trauma
5 February 2022 - A $35,000 treatment at the forefront of medical technology which pumps electric pulses into the spine ...
Posted by Michael Wonder on 04 Feb 2022
FDA approves treatment for adults with rare type of anaemia
4 February 2022 - FDA has approved Enjaymo (sutimlimab-jome) infusion to decrease the need for red blood cell transfusion due to ...
Posted by Michael Wonder on 04 Feb 2022
First gene therapy for rare genetic neurodegenerative disorder in children, recommended in NICE draft guidance
4 February 2022 - Children with a rare, fatal, genetic disorder will be able to benefit from a new one-off treatment ...